This technology is a diagnostic tool designed to help match patients to specific drugs or therapies to treat chronic ischemic heart failure. The platform focuses on immune cells called macrophages, which play a crucial role in the body's response to injury and disease. By promoting a specific type of macrophage known to aid healing, this system supports the development and testing of new therapies. It also helps ensure the quality of these treatments and creates companion diagnostic tools to guide patient care during clinical trials. The technology has been tested in various animal models, helping pave the way for its potential use in humans. Background: Chronic ischemic heart failure is a condition where the heart cannot pump enough blood due to reduced blood flow, often leading to debilitating symptoms and poor quality of life. Current treatments mainly focus on managing symptoms and slowing disease progression but often fall short in fully restoring heart function or reversing damage. Existing therapies rarely address the underlying immune responses that contribute to heart tissue damage and insufficient repair. This new technology aims to revolutionize treatment by targeting the immune system, specifically macrophages, which are crucial for healing and inflammation. Unlike conventional treatments, this approach predicts patient response to immune modulatory therapies by analyzing blood cells, offering a more personalized treatment strategy. It also facilitates the rapid screening of potential new therapies and ensures their quality before they reach patients. This method's unique ability to promote healing macrophage types directly within the body sets it apart, potentially offering more effective and lasting solutions for chronic ischemic heart failure and other immune-related conditions. Applications:
Advantages: